Ergocristine
Ergocristine, a dopamine agonist, can block prolactin release without any noticeable latent period.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
SSRN2024, 4937625.
Sci Rep.2024, 14(1):3684.
Pak J Pharm Sci.2019, 32(6):2879-2885
Viruses2023, 15(6), 1377
Applied Biological Chemistry2024, 67:66.
Front Pharmacol.2021, 12:652860.
Mol Med Rep.2022, 26(4):299.
J Biomol Struct Dyn.2022, 5;1-17.
Int J Pharmacol2020, 16:1-9
Prev Nutr Food Sci.2024, 29(4):563-571.
Related and Featured Products
Canadian Journal of Physiology & Pharmacology, 1979, 57(11):1313-1316.
Effect of ergocristine on prolactin secretion in the male rat with pituitaries grafted beneath the kidney capsule.[Reference:
WebLink]
METHODS AND RESULTS:
Male rats in which three pituitaries were grafted beneath the kidney capsule showed approximately a fourfold increase in circulating plasma prolactin concentration. The elevated plasma prolactin concentration did not remain at a constant level but fluctuated with time. The elevated prolactin concentration declined immediately after a single bolus injection of Ergocristine (30 micrograms/kg). The slope of the prolactin decay curve, determined by sequential blood sampling, was parallel to a theoretical slope having a 7-min half-life.
CONCLUSIONS:
This result indicates that Ergocristine blocked prolactin secretion immediately and completely as the decay curve (T 1/2 = 6.5 min, confidence interval 4.5--11.3) resulting from the administration of Ergocristine is the same as the endogenous prolactin decay curve (T 1/2 = 7 min).
Cell and Tissue Research, 1983, 232(2):249-256.
Extensive ultrastructural changes in rat mammotrophs following administration of the dopamine agonist ergocriptine-reflecting inhibition of prolactin release.[Reference:
WebLink]
We have demonstrated an extensive reorganization of organ elles in mammotrophs immediately following administration of Ergocristine (a dopamine agonist) to estradiol-primed male rats.
METHODS AND RESULTS:
Our ultrastructural findings are consistent with our previous results that Ergocristine can block prolactin release without any noticeable latent period. Following three-week priming of male rats with estradiol implants, Ergocristine was administered by a bolus injection through an indwelling cannula. Within two min of its administration, Ergocristine induced dramatic changes in the ultrastructure of mammotrophs, i.e., (1) increased numbers of secretory granules, (2) peripheral relocation of rough endoplasmic reticulum which tends to sequester secretory granules, (3) change in location of nucleus and (4) increased numbers of intracellular bodies associated with secretory granules.
CONCLUSIONS:
We suggest that the extensive ultrastructural changes that occurred in such a short period following Ergocristine administration may be indications of specific factors associated with blockage of hormone release.
